Exelixis Inc (EXEL) 2.48 $EXEL
Exelixis Up 7.9%, Shares Break Through Resistance (EXEL)
Comtex SmarTrend(R) - Fri Feb 13, 12:38PM CST
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 7.9% to $2.46 on 1.0x average daily volume. Thus far today, Exelixis has traded 3.3 million shares, vs. average volume of 3.2 million shares per day. The stock has outperformed the Dow (7.9% to the Dow's 0.1%) and outperformed the S&P 500 (7.9% to the S&P's 0.1%) during today's trading.
EXEL: 2.48 (+0.20)
Exelixis (EXEL) Is Today's Strong On High Volume Stock
at The Street - Wed Feb 11, 9:01AM CST
Trade-Ideas LLC identified Exelixis (EXEL) as a strong on high relative volume candidate
EXEL: 2.48 (+0.20)
Exelixis (EXEL) Catches Eye: Stock Adds 15.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 7:51AM CST
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise almost 16% on the day.
AFFX: 11.45 (+0.02), EXEL: 2.48 (+0.20)
Why Exelixis Inc.'s Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 10, 2:22PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Source: Exelixis What's Happening:...
EXEL: 2.48 (+0.20)
4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More
at The Street - Tue Feb 10, 1:01PM CST
Keep these under-$10 biotech stocks on your breakout trading radar.
AMRN: 1.18 (unch), FOLD: 8.36 (-0.11), MEIP: 5.00 (-0.04), EXEL: 2.48 (+0.20)
Follicular Thyroid Cancer Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 11:31AM CST
The report "Follicular Thyroid Cancer - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer. Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/follicular-t...eport.html.
PFE: 34.64 (-0.23), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), EXEL: 2.48 (+0.20)
Buying This Biotech Is Like Purchasing a Lottery Ticket
Motley Fool Staff - Motley Fool - Sun Feb 08, 11:59AM CST
Source: Flickr user Mark Ou . The lottery may be a fun distraction, but it's no way to plan for your future financial security. Despite that fact, everyday investors make big bets on high-risk stocks that are at best big-time gambles and at worst...
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), AEGR: 25.15 (+0.88), EXEL: 2.48 (+0.20)
Why Exelixis, Inc. Shares Surged Higher By 30% in January
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 05, 7:15AM CST
EXEL data by YCharts What: Shares of Exelixis , a small-cap biotechnology company focused on developing novel therapies to treat cancer, surged higher by 30% in January per S&P Capital IQ after announcing that it had restructured its...
EXEL: 2.48 (+0.20)
Exelixis reports February 24
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:40PM CST
EXEL: 2.48 (+0.20)
Exelixis to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 24, 2015
Business Wire - Mon Feb 02, 3:05PM CST
Exelixis, Inc. (NASDAQ: EXEL) announced today that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 24, 2015 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the Company's website.
EXEL: 2.48 (+0.20)
Exelixis to Present at the Leerink Global Healthcare Conference on Wednesday, February 11
Business Wire - Thu Jan 29, 3:10PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Leerink Global Healthcare Conference taking place February 11-12 in New York. The Exelixis presentation is scheduled for 11:30 a.m. EST/8:30 a.m. PST on Wednesday, February 11, 2015.
EXEL: 2.48 (+0.20)
Why Shares of Exelixis, Inc. Surged
Alex Planes, The Motley Fool - Motley Fool - Wed Jan 28, 3:58PM CST
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service... we hope you enjoy this complimentary peek! What's happening? Shares of Exelixis have leapt 14%...
EXEL: 2.48 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 11:44AM CST
RDWR: 20.85 (+0.42), ABMD: 60.39 (+0.46), EA: 56.39 (+0.20), ETH: 27.00 (-0.24), PSTI: 2.91 (+0.01), SALT: 2.17 (+0.18), NBG: 1.61 (+0.18), SR: 1.25 (+0.08), TUP: 72.53 (+0.44), SMLR: 4.54 (+0.20), ALDX: 11.01 (-0.25), LRE: 8.46 (+0.24), BBG: 12.56 (+0.55), MPO: 1.00 (-0.02), APRI: 1.84 (-0.08), CBLI: 3.24 (+0.05), FTK: 17.49 (+0.78), FSL: 37.53 (+2.83), X: 26.36 (+1.12), EXEL: 2.48 (+0.20)
Exelixis (EXEL) Flagged As Strong On High Volume
at The Street - Wed Jan 28, 9:01AM CST
Trade-Ideas LLC identified Exelixis (EXEL) as a strong on high relative volume candidate
EXEL: 2.48 (+0.20)
This Popular Beverage Could Be Responsible For a 20% Reduction in Melanoma Risk
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 26, 6:34AM CST
Source: National Cancer Institute via Wikimedia Commons. Cancer in any form is terrifying, but an aggressive form of skin cancer known as melanoma is establishing itself as particularly worrisome. Even though five-year survival rates for...
MRK: 58.81 (-0.07), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), EXEL: 2.48 (+0.20)
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 11, 9:03AM CST
Are you good at spotting patterns? Most of us are. We even spot patterns when they're really not there -- like seeing faces in clouds. The list below of 2014's top 10 stocks with a market cap above $300 million, however, reveals a very real pattern...
AVNR: 16.96 (unch), NPSP: 45.88 (+0.03), AGIO: 118.55 (+0.11), CELG: 115.88 (+0.16), EXEL: 2.48 (+0.20)
Bullish breakout for Exelixis
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:03AM CST
EXEL: 2.48 (+0.20)
Hot Stock: Exelixis, Shares Gain 10.4% (EXEL)
Comtex SmarTrend(R) - Thu Jan 08, 10:05AM CST
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 10.4% to $1.80 on 1.7x average daily volume. Exelixis has traded 4.7 million shares thus far today, vs. average volume of 2.8 million shares per day. The stock has outperformed the Dow (10.4% to the Dow's 1.6%) and outperformed the S&P 500 (10.4% to the S&P's 1.6%) during today's trading.
EXEL: 2.48 (+0.20)
Update: My Take On Exelixis' New Agreement With Sobi To Provide COMETRIQ In Europe
Christopher F. Davis - at Seeking Alpha - Wed Jan 07, 10:50AM CST
EXEL: 2.48 (+0.20)
Exelixis Up 7.9%, Shares Break Through Resistance (EXEL)
Comtex SmarTrend(R) - Fri Feb 13, 12:38PM CST
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 7.9% to $2.46 on 1.0x average daily volume. Thus far today, Exelixis has traded 3.3 million shares, vs. average volume of 3.2 million shares per day. The stock has outperformed the Dow (7.9% to the Dow's 0.1%) and outperformed the S&P 500 (7.9% to the S&P's 0.1%) during today's trading.
EXEL: 2.48 (+0.20)
Exelixis (EXEL) Is Today's Strong On High Volume Stock
at The Street - Wed Feb 11, 9:01AM CST
Trade-Ideas LLC identified Exelixis (EXEL) as a strong on high relative volume candidate
EXEL: 2.48 (+0.20)
Exelixis (EXEL) Catches Eye: Stock Adds 15.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 7:51AM CST
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise almost 16% on the day.
AFFX: 11.45 (+0.02), EXEL: 2.48 (+0.20)
Why Exelixis Inc.'s Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 10, 2:22PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Source: Exelixis What's Happening:...
EXEL: 2.48 (+0.20)
4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More
at The Street - Tue Feb 10, 1:01PM CST
Keep these under-$10 biotech stocks on your breakout trading radar.
AMRN: 1.18 (unch), FOLD: 8.36 (-0.11), MEIP: 5.00 (-0.04), EXEL: 2.48 (+0.20)
Follicular Thyroid Cancer Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 11:31AM CST
The report "Follicular Thyroid Cancer - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer. Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/follicular-t...eport.html.
PFE: 34.64 (-0.23), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), EXEL: 2.48 (+0.20)
Buying This Biotech Is Like Purchasing a Lottery Ticket
Motley Fool Staff - Motley Fool - Sun Feb 08, 11:59AM CST
Source: Flickr user Mark Ou . The lottery may be a fun distraction, but it's no way to plan for your future financial security. Despite that fact, everyday investors make big bets on high-risk stocks that are at best big-time gambles and at worst...
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), AEGR: 25.15 (+0.88), EXEL: 2.48 (+0.20)
Why Exelixis, Inc. Shares Surged Higher By 30% in January
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 05, 7:15AM CST
EXEL data by YCharts What: Shares of Exelixis , a small-cap biotechnology company focused on developing novel therapies to treat cancer, surged higher by 30% in January per S&P Capital IQ after announcing that it had restructured its...
EXEL: 2.48 (+0.20)
Exelixis reports February 24
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:40PM CST
EXEL: 2.48 (+0.20)
Exelixis to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 24, 2015
Business Wire - Mon Feb 02, 3:05PM CST
Exelixis, Inc. (NASDAQ: EXEL) announced today that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 24, 2015 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the Company's website.
EXEL: 2.48 (+0.20)
Exelixis to Present at the Leerink Global Healthcare Conference on Wednesday, February 11
Business Wire - Thu Jan 29, 3:10PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Leerink Global Healthcare Conference taking place February 11-12 in New York. The Exelixis presentation is scheduled for 11:30 a.m. EST/8:30 a.m. PST on Wednesday, February 11, 2015.
EXEL: 2.48 (+0.20)
Why Shares of Exelixis, Inc. Surged
Alex Planes, The Motley Fool - Motley Fool - Wed Jan 28, 3:58PM CST
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service... we hope you enjoy this complimentary peek! What's happening? Shares of Exelixis have leapt 14%...
EXEL: 2.48 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 11:44AM CST
RDWR: 20.85 (+0.42), ABMD: 60.39 (+0.46), EA: 56.39 (+0.20), ETH: 27.00 (-0.24), PSTI: 2.91 (+0.01), SALT: 2.17 (+0.18), NBG: 1.61 (+0.18), SR: 1.25 (+0.08), TUP: 72.53 (+0.44), SMLR: 4.54 (+0.20), ALDX: 11.01 (-0.25), LRE: 8.46 (+0.24), BBG: 12.56 (+0.55), MPO: 1.00 (-0.02), APRI: 1.84 (-0.08), CBLI: 3.24 (+0.05), FTK: 17.49 (+0.78), FSL: 37.53 (+2.83), X: 26.36 (+1.12), EXEL: 2.48 (+0.20)
Exelixis (EXEL) Flagged As Strong On High Volume
at The Street - Wed Jan 28, 9:01AM CST
Trade-Ideas LLC identified Exelixis (EXEL) as a strong on high relative volume candidate
EXEL: 2.48 (+0.20)
This Popular Beverage Could Be Responsible For a 20% Reduction in Melanoma Risk
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 26, 6:34AM CST
Source: National Cancer Institute via Wikimedia Commons. Cancer in any form is terrifying, but an aggressive form of skin cancer known as melanoma is establishing itself as particularly worrisome. Even though five-year survival rates for...
MRK: 58.81 (-0.07), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), EXEL: 2.48 (+0.20)
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 11, 9:03AM CST
Are you good at spotting patterns? Most of us are. We even spot patterns when they're really not there -- like seeing faces in clouds. The list below of 2014's top 10 stocks with a market cap above $300 million, however, reveals a very real pattern...
AVNR: 16.96 (unch), NPSP: 45.88 (+0.03), AGIO: 118.55 (+0.11), CELG: 115.88 (+0.16), EXEL: 2.48 (+0.20)
Bullish breakout for Exelixis
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:03AM CST
EXEL: 2.48 (+0.20)
Hot Stock: Exelixis, Shares Gain 10.4% (EXEL)
Comtex SmarTrend(R) - Thu Jan 08, 10:05AM CST
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 10.4% to $1.80 on 1.7x average daily volume. Exelixis has traded 4.7 million shares thus far today, vs. average volume of 2.8 million shares per day. The stock has outperformed the Dow (10.4% to the Dow's 1.6%) and outperformed the S&P 500 (10.4% to the S&P's 1.6%) during today's trading.
EXEL: 2.48 (+0.20)
Update: My Take On Exelixis' New Agreement With Sobi To Provide COMETRIQ In Europe
Christopher F. Davis - at Seeking Alpha - Wed Jan 07, 10:50AM CST
EXEL: 2.48 (+0.20)
